Skip to main content
. 2020 Dec;9(6):2391–2400. doi: 10.21037/tlcr-20-1252

Table 2. Tumor response in all patients.

Best response IBP group Non-IBP group P value
CR, n (%) 0 (0) 0 (0)
PR, n (%) 6 (15.4) 10 (11.6)
SD, n (%) 29 (74.3) 43 (50.0)
PD, n (%) 4 (10.3) 33 (38.4)
ORR, n (%) 6 (15.4) 10 (11.6) 0.560
DCR, n (%) 35 (89.7) 53 (61.6) 0.001

CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; DCR, disease control rate; IBP, immunotherapy beyond progression.